Xylometazoline with ipratropium nasal
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Nasal spray containing xylometazoline hydrochloride and ipratropium bromide.
Nasal congestion (topical treatment)
Symptomatic treatment of nasal congestion and rhinorrhea associated with common colds.
1 spray into each nostril up to three times a day with at least 6 hours between doses. The total daily administration should not exceed 3 sprays into each nostril.
Treatment should not exceed seven days.
Once control of symptoms has been established, it is recommended to cease treatment even before maximum duration of seven days.
Actuate pump 4 times before first application. During use, if spray does not eject or if medication has not been used for longer than six days, reprime with 4 actuations.
Children under 18 years
Recent nasal surgery
Precautions and Warnings
Predisposition to narrow angle glaucoma
Predisposition to paralytic ileus
Benign prostatic hyperplasia
Bladder outflow obstruction
Long QT syndrome
Not suitable for use in rhinitis sicca
Advise ability to drive/operate machinery may be affected by side effects
Avoid spray in or near eyes
If accidental contact with the eyes occurs, rinse thoroughly with water
Treatment should be for a maximum period of 7 days
Advise patient to consult a doctor if symptoms persist despite treatment
Pregnancy and Lactation
Use xylomatazoline and ipratropium bromide nasal spray with caution during pregnancy.
The manufacturer recommends this medication is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies are inadequate regarding effects on pregnancy, embryonal/foetal development, parturition and postnatal development. At the time of writing there is limited human data available. Risks are unknown.
Use xylomatazoline and ipratropium bromide nasal spray with caution during breastfeeding.
The manufacturer recommends this medication is not used during breastfeeding unless the potential benefit to the mother outweighs the potential risk to the infant. It is unknown if xylometazoline and ipratropium bromide are excreted into breast milk but systemic exposure is low and effects on the breastfed infant are unlikely.
Disturbances in accommodation
Dryness and irritation of eyes
Increased intra-ocular pressure
Narrow angle glaucoma
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: October 2019
Summary of Product Characteristics: Otrivine Extra Dual Relief nasal spray, solution. GlaxoSmithKline Consumer Healthcare (UK) Trading Limited.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.